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Abstract
Multiple myeloma (MM) is a frequently incurable hematological cancer in which overactivity of 
MYC plays a central role, notably through up-regulation of ribosome biogenesis and translation. 
To better understand the oncogenic program driven by MYC and investigate its potential as a 
therapeutic target, we screened a chemically diverse small-molecule library for anti-MM activity. 
The most potent hits identified were rocaglate scaffold inhibitors of translation initiation. 
Expression profiling of MM cells revealed reversion of the oncogenic MYC-driven transcriptional 
program by CMLD010509, the most promising rocaglate. Proteome-wide reversion correlated 
with selective depletion of short-lived proteins that are key to MM growth and survival, most 
notably MYC, MDM2, CCND1, MAF, and MCL-1. The efficacy of CMLD010509 in mouse 
models of MM confirmed the therapeutic relevance of these findings in vivo and supports the 
feasibility of targeting the oncogenic MYC-driven translation program in MM with rocaglates.
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INTRODUCTION
Multiple myeloma (MM) is a hematological malignancy characterized by a clonal 
proliferation of plasma cells in the bone marrow micro-environment (1). According to the 
National Cancer Institute (NCI), the prevalence of MM was estimated at 89,650 people in 
the United States in 2012, with an annual incidence of 6.3 new cases per 100,000 individuals 
and a 5-year overall survival (OS) of 46.6% (2). Despite notable therapeutic advances, MM 
remains a frequently incurable hematological malignancy. Therefore, there is an urgent 
unmet need for the development of therapeutic options with new mechanisms of action in 
MM.
The transcription factor MYC plays a central role in the progression of the disease. About 
two-thirds of patients who are newly diagnosed with MM harbor MYC activation, which 
correlates with adverse clinical outcome (3). In about 20 to 40% of the patients, this is 
explained by translocations that involve the MYC locus (4, 5). Another 10% of patients 
harbor a gain of 8q24 comprising MYC (6). MYC is centrally positioned in cell growth and 
cancer regulatory networks. MYC heterodimerizes with MAX, to bind the E-box element 
CACGTG. Functional categories of MYC-induced genes include cell growth (ribosome 
biogenesis and protein synthesis), cell cycle control, energy production (glycolysis, 
glutaminolysis, and mitochondrial biogenesis), anabolic metabolism (synthesis of amino 
acids, nucleotides, and lipids), and DNA replication (7).
Alterations in ribosome synthesis and translation activity are a defining feature of most 
cancer cells, satisfying the increased anabolic demands associated with malignant 
transformation and tumor growth. MYC directly enhances transcription genes encoding 
ribosomal proteins, ribosomal RNA, and proteins of the translation initiation complex. The 
ribosome and translation initiation complexes have historically been perceived as passive 
complexes, supporting protein synthesis without having an active role in directing functional 
expression of the genome. However, recent studies have revealed that ribosome biogenesis 
and translation activity are highly regulated to drive specific translation programs, 
independent of the genetic makeup of the cancer (8–10), and represent a crucial node for 
hyperactivation of oncogenic downstream signaling in cancer cells (11). Accordingly, 
ribosome biogenesis and translation initiation potentially provide very attractive targets for 
cancer therapy.
Here, we sought to identify chemical compounds that disrupt ribosome biogenesis and 
translation activation in MM. We also describe analogs of the rocaglate natural product class 
as very potent compounds, which inhibit the oncogenic translation program supporting MM.
RESULTS
MYC and translation activation in MM
To examine potential correlation between MYC expression and translation activation in 
MM, we analyzed the Cancer Cell Line Encyclopedia (CCLE), a large database of gene 
expression profiling for more than 1000 human cancer cell lines. We first generated a Z 
score for each cell line by combining two KEGG (Kyoto Encyclopedia of Genes and 
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Genomes) canonical pathway gene sets: ribosomal biogenesis and translation. We found a 
significant correlation between MYC expression and translation activation across the ~1000 
CCLE cell lines (R = 0.478, P < 0.001) (Fig. 1A). In particular, many MM cell lines had 
increased MYC expression and an enrichment of ribosomal biogenesis and translation (high 
Z score), which was also observed in other hematological malignancies (fig. S1). We used 
MM patient tumor cell–derived gene expression profiling (GSE6477 and GSE16558) to 
further confirm the enrichment of translation (Fig. 1B) and ribosomal biogenesis (Fig. 1C) in 
the context of high MYC expression. These results establish a strong correlation between 
MYC expression and translation activity in MM.
Identification of rocaglate derivatives
To identify a chemical biological probe with which to perturb lymphoid malignancies in the 
context of MYC overexpression, we screened a diverse small-molecule library (2812 
compounds) provided by the Boston University Center for Molecular Discovery (BU-CMD). 
The BU-CMD screening collection is composed largely of compounds synthesized using 
diversity-oriented synthesis techniques, as well as synthetic analogs of bioactive natural 
product scaffolds, assembled with the goal of accessing greater structural complexity and a 
broader coverage of chemical space than is possible with conventional combinatorial 
chemistry–based libraries (12). Two lymphoid cell lines with high expression of MYC were 
used: NCI-H929 (MM) and NAMALWA (Burkitt lymphoma). We identified 45 compounds, 
which potently inhibited proliferation of at least one of the cell lines (Fig. 2A and fig. S2). 
We validated these 45 hits in five MM cell lines and one Burkitt lymphoma cell line (Fig. 
2B). On the basis of their structure-activity relationships (SARs), this secondary validation 
highlighted three compounds (CMLD010331, CMLD010332, and CMLD009433), all 
totally synthetic analogs of the rocaglate natural product class (fig. S2B). These three 
compounds were the most active inhibiting proliferation of MM cells to a level similar to 
that of bortezomib (Fig. 2B).
Rocaglate (flavagline) natural products (and synthetic analogs) are recognized to inhibit 
protein synthesis (13, 14). To better define the activity of rocaglate derivatives against MM 
cells, we performed a follow-up SAR study involving 40 additional structurally related 
compounds (Fig. 3A and fig. S2C). These included synthetic samples of both natural and 
nonnatural rocaglates. Of the set, the compound CMLD010509 [SDS-1-021 (13, 15)] was 
identified as the most potent compound, with a median inhibitory concentration (IC50) 
below 10 nM for most MM cell lines tested (Fig. 3, B and C). The compound was less 
effective against lung and breast cancer cell lines, with an IC50 of ~30 nM (Fig. 3D).
Gene expression altered by CMLD010509 inhibiting translation in MM
To further define the mode of action for CMLD010509 against MM, we performed RNA 
sequencing (RNA-seq) on drug-versus dimethyl sulfoxide (DMSO)–treated cells in five 
different MM cell lines. We identified 845 and 475 genes that were significantly up-
regulated (table S1A) and down-regulated (table S1B), respectively, with a fold change 
higher than 2 and a P value of <0.05 (Fig. 4A). Several zinc finger transcription factors were 
among the top up-regulated genes, whereas ribosomal proteins and heat shock proteins were 
among the most significantly down-regulated (Fig. 4A). Furthermore, we defined four 
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clusters by arranging the significantly altered gene sets in a network enrichment map (16). 
The transcription and posttranslational clusters were enriched in CMLD010509-treated cells, 
whereas oxidative phosphorylation and translation clusters were enriched in control cells, 
indicating down-regulation in CMLD010509-treated cells (Fig. 4B and table S1C). The most 
significantly up-regulated genes were highly enriched for transcriptional activation, and the 
most significantly down-regulated genes were highly enriched for ribosome components and 
translation (Fig. 4C and table S1, D and E). This transcriptome profile has been associated 
with low translational flux and consequent inactivation of heat shock factor 1 (HSF1) (17). 
Here, inhibition of translation reverses constitutive HSF1 activation in cancers, thereby 
leading to extensive remodeling of the transcriptome. We confirmed that CMLD010509 
inhibits the heat shock response in MM cells, as indicated by decreased HSP70 and HSP90 
mRNA and down-regulation of the HSF1 program in CMLD010509-treated cells by 
pathway analysis (fig. S3A). To assess whether HSF1 is constitutively activated in MM, we 
used a previously published HSF1 activation signature (18) to interrogate publicly available 
data sets. We observed that this HSF1 activation signature was increased in MM cells 
compared to normal plasma cells (19, 20) and correlated with poor clinical outcome in MM 
(fig. S3, B and C) (20, 21).
To further characterize the link between CMLD010509 and translation inhibition, we used 
our CMLD010509 expression signature to query the Library of Integrated Network–Based 
Cellular Signatures (LINCS) National Institutes of Health (NIH) program 
(www.lincscloud.org). The LINCS database is a large catalog of perturbational gene 
expression profiles across 77 cell lines. It includes over 20,000 chemical compounds and 
more than 22,000 genetic perturbations (knockdown and overexpression of genes). The most 
significant positive correlations with the CMLD010509 signature were represented by 
known translation inhibitors such as emetine, omacetaxine, and cephaeline, as well as 
knockdown of ribosome subunits and translation initiation factors (Fig. 4D and table S1F). 
These results are consistent with the potent activity of CMLD010509 as a translation 
inhibitor.
MYC knockdown was one of the perturbations with the most positive correlation with our 
compound signature. The GSEA of our compounds’ effects using the RNA-seq data revealed 
that several MYC gene sets were among the most significantly enriched compared to the 
DMSO control cells, indicating a down-regulation of the entire MYC pathway in 
CMLD010509-treated cells (Fig. 4E). Several MYC target genes were down-regulated by 
the drug; however, the amounts of MYC transcript were not decreased in CMLD010509-
treated cells, indicating posttranscriptional regulation of MYC activity (Fig. 4F). Together, 
these results reinforce the role of MYC in translation activation in MM and the mechanistic 
action of CMLD010509 as a translation inhibitor in MM cells.
Disruption of the oncogenic translation program in MM by CMLD010509
To better define the consequences of CMLD010509-induced translation inhibition, we 
performed an unbiased, proteome-wide experiment in a quantitative and highly parallel 
format (22). We compared the immediate impact of CMLD010509 treatment (100 nM) to 
that of vehicle control in NCI-H929 cells. Exposure for 2 hours was selected to identify 
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primary, immediate consequences of compound action and to mitigate expected, 
confounding effects of suppressed CMLD010509 target proteins. Each treatment condition 
was prepared in three biological replicates and individually labeled using isobaric tagging. 
We identified 7312 proteins, of which 54 were significantly depleted by more than twofold 
after CMLD010509 exposure (P < 0.05; fold change, >2) (Fig. 5A and table S2A). Several 
key oncoproteins in MM were among the proteins most depleted by the compound, 
including MYC, MDM2, CCND1, MCL-1, and MAF. MYC is overexpressed in about 40% 
of MM by either translocations or gain of 8q24, among other potential epigenetic regulations 
(4, 5). CCND1 is overexpressed in about 20% of MM in the case of t(11;14) or focal gain in 
11q13 (4, 23). MDM2 is an ubiquitin ligase (E3) that acts as a negative regulator of p53 
(24). MCL-1 belongs to the Bcl-2 family and is one of the driver oncogenes in gain-of-1q 
cancers (25). MAF is frequently overexpressed in MM in relation to t(14;16) (26).
To further study the mechanism of action of CMLD010509, we compared the protein fold 
changes to the transcript fold changes in CMLD010509- versus vehicle-treated cells (Fig. 
5B). The large majority of depleted proteins had a change in transcript amount of less than 
twofold, indicative of a selective translation inhibitory mode of action for CMLD010509. To 
validate these findings, we measured MYC, MDM2, CCND1, MCL-1, and MAF by 
immunoblotting and quantitative real-time polymerase chain reaction (qRT-PCR) after 
compound treatment as above (100 nM, 2 hours). All five genes were depleted at the protein 
level, whereas the amounts of each transcript were unchanged or slightly increased (Fig. 5, 
C and D), consistent with post-transcriptional effects of CMLD010509. Similar results were 
observed in six additional MM cell lines (fig. S4, A to G). To assess whether the targeted 
proteins were directly depleted by inhibiting their synthesis, we pulse-labeled cells with 35S-
cysteine/methionine and immunoprecipitated the proteins of interest. In the presence of 
CMLD010509, we observed selective inhibition of new translation for MYC, CCND1, and 
MCL-1 as opposed to housekeeping proteins such as glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (fig. S4H).
To further establish pathways affected by CMLD010509, we queried the 54 proteins with 
more than twofold depletion against the KEGG database. Cancer pathways were highly 
enriched among these depleted proteins, representing a distinct cluster by network 
enrichment analysis (Fig. 6A and table S2B). Moreover, when interrogating the whole 
MSigDB C2 canonical pathway database (representing 1330 gene sets), we found that the 
most highly enriched pathways consisted of MM pathways: IRF4 and MYC targets. This 
result indicates that a significant number of CMLD010509-depleted proteins are present in 
the IRF4 and MYC pathways (P < 0.001), as defined by the GSEA transcriptional pathways. 
IRF4 is a key transcription factor essential for plasma cell differentiation, upon which MM 
cells are dependent on (Fig. 6B and table S2C) (27), suggesting that CMLD010509 inhibits 
translation of key oncoproteins in MM. To determine whether this translational program is 
specific for MM, we used the signature of 54 proteins to calculate Z scores for over 1000 
cell lines across the CCLE database. The CMLD010509 signature was enriched in MM cell 
lines at the transcriptional level compared to other cancer cell lines (Fig. 6C). Furthermore, 
the signature was also significantly enriched in plasma cells of patients with MM compared 
to that of healthy donors (P < 0.05), in two independent gene expression profiling 
experiments including patients at diagnosis (GSE16558) and at relapse (GSE6477) (Fig. 
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6D). Together, these results demonstrate that CMLD010509 inhibits the translation of key 
oncoproteins, supporting the proliferation and survival of MM.
Induction of apoptosis in MM cells by CMLD010509
We next explored the antiproliferative consequences of inhibiting the oncogenic translation 
program in MM cells with CMLD010509. The drug was associated with a strong induction 
of an apoptotic response in NCI-H929 and MM1S cells, as measured by caspase-3 and 
caspase-7 activation (Fig. 7A) and cleavage of both poly[adenosine 5′-diphosphate–ribose] 
polymerase (PARP) and caspase-3 (Fig. 7B). Kinetic studies revealed a rapid apoptotic 
response to CMLD010509 at 3 hours, associated with depletion of MYC and MCL-1 even at 
low concentrations (10 nM) (Fig. 7C). We next assessed the in vitro activity of 
CMLD010509 against human peripheral blood mono-nuclear cells (PBMCs) and found no 
cytotoxicity, suggesting the potential for a useful therapeutic window for this agent against 
MM (fig. S5).
In vivo suppression of MM by CMLD010509
On the basis of the mechanism of action of CMLD010509 in MM, we assessed whether the 
drug would be effective and tolerable in animal models. We first established a xenograft 
model by intravenous injection of MM1S cells expressing luciferase (luc) into severe 
combined immunodeficient (SCID) mice. After engraftment, the mice were randomized to 
vehicle and compound treatment groups, with equal amounts of bioluminescence imaging 
(BLI) intensity in each group. CMLD010509 or vehicle control was administered via 
intraperitoneal injection at 0.7 mg/kg twice a week (Fig. 8A). CMLD010509 caused a 
marked reduction in tumor burden despite the very rapid growth of this aggressive MM cell 
line, as monitored by BLI and prolonged survival (median OS, 35 versus 47 days; P < 0.001) 
(Fig. 8, B and C). Notably, 4 weeks of CMLD010509 treatment were well tolerated with 
preservation of body weight and normal complete blood counts (fig. S6, A to C). To confirm 
the in vivo efficacy of CMDL010509, we used a second xenograft model consisting of SCID 
mice inoculated intravenously with KMS-11 cells. The mice were treated with 
intraperitoneal injections of either CMLD010509 at 0.7 mg/kg or vehicle control twice a 
week, starting at week 4, and were sacrificed at week 8. Immunohistochemistry studies were 
conducted on bone marrow samples to assess the presence of CD138+ tumor cells as well as 
amounts of MYC and Ki-67 protein. A decrease in CD138+ plasma cells, depletion of MYC, 
and inhibition of proliferation (Ki-67 staining) were observed in mice treated with 
CMLD010509 compared to those treated with vehicle control (Fig. 8D), further validating 
the activity of CMLD010509 on MM cell lines in vivo.
Finally, to complete the assessment of CMLD010509’s effects on MYC-driven MM cells in 
vivo, we used an immunocompetent mouse model, in which transplantable mouse MM cells 
were injected into C57BL/6 mice. The tumor cells are driven by plasma cell–specific MYC 
overexpression (Vk*Myc cells) (28). Mice were treated with either CMLD010509 at 0.7 
mg/kg or vehicle control intraperitoneally twice a week, beginning 1 week after cell tumor 
inoculation. Treatment was well tolerated, as indicated by normal transthyretin and albumin 
serum concentrations at 6 weeks (fig. S6D). Serum electrophoresis proteins (SPEPs) 
revealed a robust decrease of M-spike in CMLD010509-treated mice as shown at week 4 
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(Fig. 8E), which was associated with a significantly prolonged survival—median survival of 
39 days in the control group versus not reached in the CMLD010509-treated group at this 
end of the experiment (90 days) (P = 0.0019) (Fig. 8F). Together, these data indicate that 
CMLD010509 is highly active and well tolerated in vivo in several mouse models of MM.
DISCUSSION
The oncogenic translation program of tumors is supported by aberrant activation of 
ribosome biogenesis and dysregulation of the translation initiation machinery (8–10). Here, 
we report the correlation between MYC activation and the translation of an oncogenic 
program in MM, which can be inhibited by the rocaglate derivative CMLD010509. We 
identified the rocaglate derivative CMLD010509 (SDS-1-021) as a highly specific inhibitor 
of the oncogenic translation program supporting MM—including key oncoproteins such as 
MYC, MDM2, CCND1, MAF, and MCL-1.
Although ribosome biogenesis and translation initiation complex function have historically 
been perceived as passive processes, recent studies have revealed that they are actively 
regulated to support specific translation programs (8, 9). Here, using a proteome-wide 
approach, we report that targeting translation initiation in MM selectively depletes multiple 
oncoproteins while leaving other housekeeping proteins largely unperturbed. The selective 
inhibition of translation initiation for oncogenic mRNA in the context of cancer can be 
explained by several mechanisms. First, some messengers are translated in a cap-dependent 
manner, whereas others are translated through the internal ribosome entry site process. Cap-
dependent translation relies on the ability of the eukaryotic translation initiation factor 4F 
(eIF4F) complex to bind to the 5′ 7-methylguanosine cap present on mature mRNAs (29). 
Moreover, the presence of complex secondary structures within the 5′ untranslated region 
(5′UTR) influences mRNA translation. Transcripts with complex 5′UTR secondary 
structures are subject to greater dependence on the initiation machinery and therefore might 
be more sensitive to its inhibition. Subsequent studies have shown that the limiting factor is 
often eIF4E, mainly through its ability to recruit the eIF4A helicase (30–33). Complex 
5′UTR structures have been identified in several prooncogenic mRNAs such as those 
encoding MYC, MDM2, and cyclins (10).
Rocaglate natural products, including silvestrol and rocaglamide A, comprise a class of 
protein synthesis inhibitors (14, 17) that interact with the eIF4A—a protein subunit of the 
translation initiation complex (14, 34). These compounds increase the affinity between 
eIF4A and mRNA and specifically clamp eIF4A onto polypurine sequences in mRNA 
5′UTR, thus blocking ribosome subunit scanning and reducing protein expression from 
transcripts bearing the rocaglamide A–eIF4A target sequence (35). The compound 
CMLD010509 is a potent and selective translation inhibitor through an eIF4E 
phosphorylation–independent mechanism (15). Here, we demonstrate that CMLD010509 
inhibits translation of a key suite of oncoproteins in MM that constitute an oncogenic 
translation program supporting MM oncogenesis. Moreover, this compound is highly 
effective in vivo in several mouse models, suggesting an effective therapeutic approach 
toward targeting MYC in MM.
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The present work was aimed to assess the translational potential of rocaglates in MM. We 
did not focus on the specific relationship between MYC and translation activation in MM. 
Moreover, the specific effect of CMLD010509 on the translational oncogenic program in 
MM could be further explored to fully determine its mechanism of action.
In summary, we present an indirect but highly effective mechanism for targeting an 
oncogenic translation program frequently driven by MYC in MM. Even with the most recent 
advances in the management of plasma cell dyscrasias, MM remains a frequently incurable 
disease. Therefore, there is an urgent need for additional treatment options with new modes 
of activity. As shown here, rocaglates inhibit a specific translation oncogenic program 
related to high expression of MYC, with a very potent activity in vitro and in vivo. Thus, 
targeting dysregulated translation initiation with rocaglates rather than targeting the 
elongation machinery with other translation inhibitors might be less toxic to normal tissues. 
Several characteristics of CMLD010509 support its further preclinical development. First, 
the compound can be made by total synthesis from simple starting materials, which avoids 
reliance on limited bioresources (36). Second, its mode of action suggests a simple strategy 
for therapeutic drug monitoring to minimize toxicity in patients based on routinely available 
measurements of short-lived serum proteins such as prealbumin (transthyretin) or factor VII. 
Finally, successful clinical development might be improved by use of the oncogenic 
signature we have proposed as a potential companion diagnostic to identify patients most 
likely to benefit from rocaglate treatment. The targeting of protein degradation in MM with 
proteasome inhibitors has become a mainstay in the management of this disease. On the 
basis of the preclinical data presented here, we suggest that targeting protein homeostasis in 
the opposite way, through selective inhibition of protein synthesis, is worthy of further 
development and may provide an equally effective approach in the management of MM and 
possibly other hematological malignancies.
MATERIALS AND METHODS
Study design
The objectives of this study were as follows: (i) to identify compounds able to interfere with 
MYC activation in MM, (ii) to assess the mechanistic role of rocaglate compounds in MM, 
and (iii) to determine the preclinical efficacy of CMLD010509 as an effective treatment 
against MM. CellTiter-Glo was used to evaluate the efficacy of a small-molecule screen 
against two cell lines with high expression of MYC, to validate the best hits against six cell 
lines, and to generate IC50 values of rocaglate compounds. Functional evaluation of 
CMLD010509 was performed by RNA-seq of five MM cell lines and tandem mass tag 
(TMT) mass spectrometry using NCI-H929 exposed to CMLD010509 or DMSO in both 
cases. Further, qRT-PCR and Western blotting were performed to validate the data. We used 
GSEA and the LINCS cloud databases for pathway analyses. The effect of CMLD010509 in 
vitro was assessed on MM cell lines by Caspase-Glo 3/7 and Western blotting for caspase-3 
and PARP. To determine the preclinical efficacy of CMLD010509, we used three different 
mouse models. The first one was a xenograft model where MM1S luc/GFP cells were 
injected intravenously into SCID mice. After 2 weeks of engraftment, tumor formation was 
monitored by BLI. To allocate animals to experimental groups, we measured BLI using 
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Living Image 4.0 software and randomized mice to obtain equal amounts of BLI intensity in 
each group. Mice were treated with either CMLD010509 or DMSO and monitored weekly 
for BLI, blood count, and body weight and for survival. The second xenograft model 
consisted of injecting KMS-11 cells into SCID mice and treating them with either 
CMLD010509 or DMSO. Mice were all sacrificed at week 6 and studied for 
immunohistochemistry of the bone marrow with CD138, MYC, and Ki-67 antibodies. 
Finally, we developed an immunocompetent mouse model by injecting Vk*Myc cells into 
C57BL/6 mice. After 1 week of engraftment, mice were randomized into two groups and 
treated with either CMLD010509 or DMSO. Mice were monitored for SPEP and survival. 
The experiment was terminated after 3 months of follow-up.
Cell lines and primary cells
NCI-H929, NAMALWA, MM1S, MM1R, U266, and RPMI8226 were purchased from 
American Type Culture Collection, OPM-2 was from DSMZ, and KMS-11 and KMM-1 
were from Japanese Collection of Research Bioresources Cell Bank. MM1S luc/GFP cells 
were gifts from A. Kung (Dana-Farber Cancer Institute), and CAL51, NCI-1650, NCI-1750, 
NCI-23, DU4475, and ZR-751 cells were gifts from the Jänne Lab (Dana-Farber Cancer 
Institute). Vk*Myc cells used in this study were isolated from late-stage Vk*Myc mice (gift 
from L. Bergsagel and M. Chesi) and expanded in vivo. All cells were maintained under 5% 
CO2 in a medium according to their specifications. PMBCs were obtained from the 
peripheral blood of healthy volunteers by Ficoll gradient centrifugation.
Small-molecule screen
MM cell lines were treated with 2812 compounds provided by the BU-CMD (www.bu.edu/
cmd). A microplate dispenser, the Matrix WellMate (Thermo Fisher Scientific), was used to 
dispense 2000 adherent cells or 5000 suspension cells per well into 384-well microplates. 
Compounds were added using Biomek FX pin tool (Beckman Coulter). After treatment, 
cytotoxicity was measured by CellTiter-Glo (Promega) according to the manufacturer’s 
protocol, and luminescence signals were read using EnSpire (PerkinElmer), a plate reader.
Cell viability assay
Relative cell growth and survival were measured in a 96-well microplate format by using the 
luminescent detection of CellTiter-Glo or Caspase-Glo as the end point. For IC50, 5000 
adherent cells and 30,000 suspension cells were plated and incubated with compounds for 
72 hours. Each analysis was performed three times.
Protein and RNA isolation
Harvested cells were lysed using lysis buffer (Cell Signaling) supplemented with 5 mM NaF 
and 1 mM phenylmethylsulfonyl fluoride for 30 min on ice, and lysates were centrifuged at 
14,000g for 30 min. Protein concentration was measured using Bio-Rad Protein Assay kit. 
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol and evaluated for quantity and quality by NanoDrop 
spectrophotometer.
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Quantitative real-time PCR
For qRT-PCR, 100 ng of total RNA per sample was used for reverse transcription using the 
SuperScript III First-Strand Synthesis Kit (Invitrogen). qRT-PCR was done on a 
StepOnePlus Real-Time PCR System (Applied Biosystems) using SYBR Green I Master 
Mix. Gene expression was normalized to 18S. The primer sequences are as follows: human 
MYC, TCCGTCCTCGGATTCTCTGCTCT (forward) and 
GCCTCCAGCAGAAGGTGATCCA (reverse); human MDM2, 
CCCAAGACAAAGAAGAGAGTGTGG (forward) and 
CTGGGCAGGGCTTATTCCTTTTCT (reverse); human CCND1, 
GCTGCGAAGTGGAAACCATC (forward) and CCTCCTTCTGCACACATTTGAA 
(reverse); human MAF, CTGGCAATGAGCAACTCCGA (forward) and 
AGCCGGTCATCCAGTAGAGT (reverse); human MCL-1, 
TGCTTCGGAAACTGGACATCA (forward) and TAGCCACAAAGGCACCAAAAG 
(reverse); and human 18S, TCAACTTTCGATGGTAGTCGCCGT (forward) and 
TCCTTGGATGTGGTAGCCGTTTCT (reverse).
RNA sequencing
NCI-H929, NAMALWA, U266, MM1S, and OPM-2 cells were treated with 50 nM 
CMLD010509 or vehicle control for 6 hours. RNA was prepared as mentioned earlier. A 
starting amount of 500 ng of RNA was used to prepare polyadenylate-enriched, single bar–
coded libraries using the NEBNext Kit. Quality control of the libraries was evaluated by 
Bioanalyzer analysis with High Sensitivity chips (Agilent Technologies). Sequencing was 
performed on a HiSeq 2500 (Illumina) by 2× 50–base pair paired-end reads at the 
Biopolymers Facility of Harvard Medical School. We used Bcbio_nextgen (https://
github.com/chapmanb/bcbio-nextgen/) to process the RNA-seq data. Briefly, cutadapt 
(https://github.com/marcelm/cutadapt/) was used to trim adapters; trimmed reads were 
aligned to human reference genome (GRCh37) with to-phat2; read count for each gene was 
calculated by HTSeq. Genes with low expression (fragments per kilobase million of <1 
across all samples) were filtered out. GSEA was used to identify significantly enriched 
pathways (16), with an FDR of <0.25 and a P value of <0.05. Gene sets were downloaded 
from the Broad Institute’s MSigDB (www.broadinstitute.org/gsea/index.jsp).
Immunoblotting
Cell lysates (50 μg) were subjected to SDS–polyacrylamide gel electrophoresis (PAGE), 
transferred to a polyvinylidene fluoride membrane, blocked with 5% nonfat dry milk, and 
incubated with primary antibodies overnight at 4°C. Primary antibodies used included anti-
MYC, anti–MCL-1, anti-CCDN1 (all Cell Signaling), anti-MDM2, anti-MAF (all Santa 
Cruz Biotechnology), and anti-tubulin (Sigma-Aldrich).
TMT spectrometry
NCI-H929 cells were treated in triplicate with CMLD010509 (100 nM) or vehicle control 
for 2 hours. Proteins were isolated and further processed for quantitative proteomic analysis 
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by TMT (Thermo Fisher Scientific) as per the manufacturer’s protocol, with mass 
spectrometry.
35S labeling
NCI-H929 and MM1S cells were preincubated in methionine-free RPMI medium 
supplemented with dialyzed fetal bovine serum (FBS) and penicillin-streptomycin (Thermo 
Fisher Scientific) for 10 min. 35S-methionine was added to the medium at a final 
concentration of 100 μCi/ml (~9 μM methionine), and the cells were labeled for 20 min at 
37°C. An equal volume of complete RPMI medium (containing an excess of unlabeled 
methionine; ~50 μM final) was added, and the cells were incubated for an additional 10 min 
at 37°C. The cells were then collected by centrifugation and washed with cold 1× phosphate-
buffered saline. Whole-cell extracts were prepared by resuspending the cells in 1× Cell Lysis 
Buffer (Cell Signaling) supplemented with Halt protease and phosphatase inhibitors 
(Thermo Fisher Scientific) followed by a 30-min incubation on ice. The extracts were 
centrifuged for 15 min at 18,000g to remove the insoluble material. For the 
immunoprecipitation (IP) experiments, the whole-cell extracts were incubated with primary 
antibodies [anti-MYC (Abcam #ab32), anti-cyclin D1 (Abcam #ab134175), anti–MCL-1 
(Cell Signaling #94296), anti-GAPDH (Abcam #ab181602), or anti–control 
immunoglobulin G (Cell Signaling #3900)] overnight at 4°C with rotation. The following 
morning, 40 μl of DynaBeads Protein G (Invitrogen) was added, and the samples were 
rotated for an additional hour. The beads were separated using a magnetic rack and washed 
three times with Cell Lysis Buffer. The immunoprecipitated material was eluted in 25 μl of 
1× SDS sample buffer. The whole-cell extracts and the IP samples were resolved by SDS-
PAGE and transferred to a nitrocellulose membrane (GE Healthcare). The membrane was 
stained with Ponceau S to visualize total proteins in samples. The membrane was then air-
dried and exposed to a phosphorimager screen to visualize the 35S-labeled proteins.
In vivo studies
SCID mice (n = 10 per group) used for xenograft experiments were injected intravenously 
with 5 × 106 MM1S GFP-Luc+ and monitored by blood cell count, body weight, BLI, and 
survival. After engraftment, the mice were randomized into two groups on the basis of BLI, 
and CMLD010509 or vehicle control was administered by intraperitoneal injection at 0.7 
mg/kg twice a week. Similar studies were performed in SCID mice (n = 10 per group) by 
injecting 7 × 106 KMS-11, but because these cells are not luc+, the mice were sacrificed at 
week 6, and the bone marrow of femurs was subjected to immunohistochemistry as 
described below. For the immunocompetent mouse model, C57BL/6 mice were purchased 
from the Jackson Laboratory. The transplantable Vk*MYC cell line, which was a gift from 
M. Chesi and P. L. Bergsagel (Mayo Clinic, Scottsdale, AZ), was maintained and expanded 
in vitro using RPMI 1640 containing 10% FBS (Sigma-Aldrich), 2 mM L-glutamine, 
penicillin (100 U/ml), and streptomycin (100 μg/ml) (GIBCO). Vk*Myc cells (3.5 × 106) 
were injected intravenously into C57BL/6 mice, and the peripheral blood from the mice was 
collected for SPEP measurement at serial time points by submandibular bleeding. SPEP was 
performed using the QuickGel Protein Kit (Helena Laboratories) according to the 
manufacturer’s protocol. After 1 week of Vk*Myc cell injection, the mice were randomized 
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to therapy or vehicle control (intraperitoneal injection at 0.7 mg/kg twice a week, n = 10 
mice per group).
Study approval
All mice were treated, monitored, and sacrificed in accordance with an approved protocol of 
the Dana-Farber Cancer Institute Animal Care and Use Committee.
Immunohistochemistry
Murine tissues were fixed overnight in 10% buffered formalin and stored in 70% ethanol 
before proceeding to paraffin-embedding, sectioning, and staining with hematoxylin and 
eosin. Immunohistochemistry was performed using anti-CD138, anti–Ki-67, and anti–c-
Myc, as previously reported (37).
Statistical analysis
Unpaired Student’s t test was used to compare two independent groups. One-way analysis of 
variance (ANOVA) was used when three or more independent groups were compared. For 
survival data, Kaplan-Meier curves were plotted and compared using a log-rank test. All 
tests were two-sided. A P value of <0.05 was considered statistically significant. Pearson 
coefficient was used to assess the correlation between two groups. Analysis was performed 
with GraphPad Prism Software (GraphPad Software Inc.). Mann-Whitney U test was used to 
quantify the enrichment of a given signature in a ranked list of genes, which was represented 
as a Z score. GSEA was performed as described previously using GSEA v2.0.10 
(www.broadinstitute.org/gsea/) (16). MSigDB collections (http://software.broadinstitute.org/
gsea/msigdb/index.jsp) and specific gene sets (KEGG Translation and Ribosome and several 
MYC gene sets) were tested for their enrichment in data sets—MM patients with high 
expression of MYC versus low expression or MM cell lines treated with CMLD010509 
versus DMSO. Investigate_GeneSets (http://software.broadinstitute.org/gsea/msigdb/
annotate.jsp) was used to investigate pathways enriched in a list of genes against MSigDB 
collections. The analysis was performed by applying two-tailed Fisher’s test as implemented 
in the Investigate_GeneSets module at MSigDB. For network enrichment mapping, gene 
sets with significant enrichment in CMLD010509- or DMSO-treated cells by GSEA were 
selected on the basis of P < 0.05 and FDR < 0.25 and visualized with Cytoscape v3.3.0 
(www.cytoscape.org/cy3.html). This software organizes the significant gene sets into a 
network, where nodes correspond to gene sets, and the edges reflect significant overlap 
between the nodes according to Fisher’s test. The size of the nodes is proportional to the 
number of genes in the gene set, as previously described (38).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Correlation of MYC expression with ribosomal biogenesis and translation activity
(A) Correlation analysis of MYC expression on the y axis and the Z-score enrichment across 
over 1000 cell lines from the CCLE database. A Z score was generated for each cell line by 
combining two KEGG canonical pathway gene sets: ribosomal biogenesis and translation. 
Red dots indicate MM cell lines, and black circles indicate all CCLE cell lines except MM. 
A significant correlation between MYC expression and the translation activation was 
observed; R = 0.478, P < 0.0001. Gene Set Enrichment Analysis (GSEA) of MM patient 
tumor cell-derived gene expression profiling (GSE6477 and GSE16558) shown in (B) and 
(C), confirming enrichment of translation and ribosomal biogenesis in context of high 
expression of MYC. ES, enrichment score; FDR, false discovery rate.
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Fig. 2. Chemical library screen
(A) Small-molecule library generated by the Boston University Center (~3000 synthetic 
compounds) against NCI-H929 (MM) and NAMALWA (Burkitt lymphoma). We identified 
45 compounds with a potent inhibition of proliferation for at least one of the cell lines. (B) 
Validation of 45 hits in six cell lines harboring diverse MM driver genomic features of MM, 
showing that the most effective compounds to inhibit proliferation were in the rocaglate 
class, namely, CMLD010331, CMLD010332, and CMLD09433 (red dots). These 
compounds had similar potency to bortezomib.
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Fig. 3. High potency of rocaglate inhibitors in MM
(A) Heat map of the effects of 40 rocaglate derivatives on relative survival of MM cells 
(NCI-H929, KMS-18, MM1R, MM1S, OPM-2, RPMI8226, and U266) along with 
lymphoma cell lines (NAMALWA and MEC1) shows strong activity with low doses of the 
rocaglate compounds in these cell lines. (B) IC50 of these 40 compounds in NCI-H929 
showing that CMLD010509 was the most potent compound, with an IC50 below 10 nM. (C) 
CMLD010509 is a synthetic rocaglate derivative containing the 
cyclopenta[b]tetrahydrobenzofuran core structure. (D) IC50 of CMLD010509 showing an 
IC50 below 10 nM for most MM cell lines tested (indicated in red), whereas it was relatively 
resistant in lung and breast cancer cell lines (in black) with an IC50 of ~30 nM.
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Fig. 4. Transcription activation and translation inhibition induced by the rocaglate derivative 
CMLD010509
(A) Volcano plot of RNA-seq of drug- versus DMSO-treated cells in five different MM cell 
lines showing 845 and 475 genes significantly up- and down-regulated, respectively, with a 
fold change (FC) higher than 2. (B) Network enrichment map identifying two clusters 
enriched in CMLD010509-treated cells (transcription and posttranslational modification 
clusters) and two clusters enriched in control cells (oxidative phosphorylation and translation 
clusters). (C) Bar graphs showing the most significantly up- and down-regulated genes in 
CMLD010509-treated cells determined by querying the Molecular Signatures Database 
(MSigDB) C5 gene sets. (D) Connectivity score using LINCS NIH program with the gene 
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signature of CMLD010509 against 10,000 “pertubagen” signatures (corresponding to short 
hairpin RNA, open reading frame, and compounds). (E) GSEA analysis of CMLD010509 
using RNA-seq data. Several MYC gene sets were among the most significantly enriched 
compared to DMSO control cells. (F) Bar graphs of MYC transcript expression in MM cell 
lines and NAMALWA in CMLD010509-treated cells, normalized to DMSO control. WT, 
wild type; KD, knockdown.
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Fig. 5. Regulation of the oncogenic translation program of MM by CMLD010509
(A) Expression proteomics showing the impact of CMLD010509 treatment (100 nM) 
relative to vehicle control in NCI-H929 cells after a 2-hour incubation (three biological 
replicates were used and individually tagged using isobaric tagging). We identified 7312 
proteins, of which 54 were significantly depleted by more than twofold through 
CMLD010509 exposure (P < 0.05; fold change, >2). The most depleted proteins included 
MYC, MDM2, CCND1, MCL-1, and MAF (red dots). (B) Comparison of the protein fold 
changes to the transcript fold changes in CMLD010509- versus vehicle-treated cells. A large 
majority of depleted proteins had a transcript fold change lower than twofold, suggesting a 
specific translational mechanism of action for CMLD010509. (C) Immunoblots and (D) 
qRT-PCR analysis of MYC, MDM2, CCND1, MCL-1, and MAF in compound-treated (100 
nM, 3 hours) or vehicle-treated NCI-H929. All five genes were depleted at the protein level, 
whereas their transcripts were unchanged or slightly overexpressed.
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Fig. 6. Pathway analysis of CMLD010509
(A) Network enrichment analysis of 54 depleted proteins with more than twofold change 
analyzed in the KEGG database, showing that cancer pathways were highly enriched among 
these depleted proteins. AML, acute myeloid leukemia; CML, chronic myeloid leukemia; 
MAPK, mitogen-activated protein kinase; JAK/STAT, Janus kinase/signal transducer and 
activator of transcription. (B) The 54 depleted proteins were queried against MSigDB C2 
canonical pathway database, showing an enrichment of MM specific oncoproteins including 
IRF4 pathway. (C) Z scores of the 54 proteins evaluated on 1000 cell lines of the CCLE 
database. (D) Z scores of the 54 proteins evaluated on two independent gene expression 
profiles including patients at diagnosis (GSE16558) and at relapse (GSE6477).
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Fig. 7. Induction of apoptosis by CMLD010509
(A) Apoptosis assay measured by caspase-3 and caspase-7 activation (Caspase-Glo 3/7) at 3 
and 24 hours in NCI-H929 and MM1S cells treated with three concentrations of 
CMLD010509 versus vehicle control. (B) Immunoblots for cleavage of both PARP and 
caspase-3 in response to three concentrations of CMLD010509 in NCI-H929 and MM1S 
cells at 3 and 24 hours. (C) Immunoblots for MYC and MCL-1 in response to three 
concentrations of CMLD010509 in NCI-H929 and MM1S cells at 3 and 24 hours.
Manier et al. Page 23
Sci Transl Med. Author manuscript; available in PMC 2018 May 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 8. In vivo suppression of MM by CMLD010509
(A) Diagram of in vivo studies performed. SCID mice were injected with MM1S GFP 
(green fluorescent protein)/ Luc+. After engraftment, the mice were randomized to two 
groups based on BLI, and CMLD010509 or vehicle control was administered by 
intraperitoneal (i.p.) injections at 0.7 mg/kg two times a week. Tumor growth was assessed 
by weekly bioluminescence (BLI) counts, (B) showing a significant difference in tumor 
growth between the DMSO-treated group and the CMLD010509 group; P < 0.001. (C) 
Kaplan-Meier curve showing a significant survival difference between vehicle- and drug-
treated mice, with a median OS of 35 versus 47 days, P < 0.001. (D) Immunohistochemistry 
for CD138, Ki-67, and MYC in bone marrow samples from the KMS-11–injected mice. 
Scale bars, 50 μm. (E) Electrophoresis of serum proteins from transplantable Vk*Myc mice 
indicating the presence of a γ-globulin (M-spike) in the DMSO control group (arrow) at 4 
weeks. C57BL/6 syngeneic mice were intravenously injected with 3.5 × 106 Vk*Myc cells. 
At day 7 after tumor cells injection, mice were randomized into two groups and received 
DMSO (n = 10) or CMLD010509 drug (n = 10, 0.7 mg/kg per mouse) through 
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intraperitoneal injections twice a week. (F) Kaplan-Meier curve showing a significant 
survival difference between vehicle- and drug-treated mice, with a median OS of 39 days 
versus not reached, P = 0.0019. Statistical analyses were performed using log-rank test.
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